Efficacy and side effects of avatrombopag/sucoxin

Avatrombopag/Avatrombopag is an orally bioavailable, small-molecule thrombopoietin (TPO) receptor agonist that stimulates the proliferation and differentiation of megakaryocytes in bone marrow progenitor cells, thereby increasing platelet production. Avatrombopag is not competitive with thrombopoietin for binding to TPO receptors and has additive pharmacological effects on platelet production with TPO.

Avatrombopag is a thrombopoietin receptor (TPOR; MPL) agonist with possible megakaryopoiesis-stimulating activity. After administration, avatrombopag binds to and stimulates the platelet thrombopoietin receptor (TPOR), which can cause megakaryocytes to proliferate and differentiate from myeloid progenitor cells. This process increases platelet production and may help prevent chemotherapy-induced thrombocytopenia (CIT). TPOR is classified as a member of the cytokine receptor and hematopoietic receptor superfamilies.

In an efficacy study, avatropopag/ resulted in dose- and exposure-dependent increases in platelet counts in adults. Platelet counts begin to increase within 3 to 5 days after the start of the 5-day treatment course, with maximum results achieved after 10 to 13 days. Thereafter, the platelet count gradually decreased, returning to near baseline values u200bu200bat 35 days. Increased platelet activation leads to increased coagulation, which may lead to various complications. Avatrombopag does not result in increased platelet activation.

If the patient is between the ages of 18 and 60 years old and is not taking other drugs or has no other diseases, the side effects more likely to be encountered include fever, abdominal pain, nausea, headache, fatigue and limb edema, which are the most common side effects in patients with chronic liver disease (CLD). Headache, fatigue, easy bruising or bleeding (nosebleeds, bleeding gums), upper respiratory tract infection, joint pain, purple or red spots on the skin, and nasopharyngitis are the most common side effects in people with immune thrombocytopenia (ITP). Do not use avatrombopag if the patient is allergic to avatrombopag.